

Hull and East Riding Prescribing Committee Minutes – Confirmed

Date / Time	Wednesday 30 th May 2018
Venue	The Board Room, Health House, Willerby
Chair	Mr A Ramirez, Senior Principal Pharmacist- Interface HEY
Notes / Action Points	Mrs W Hornsby, Senior Pharmacy Technician HEY.
Quorate: Yes / No	Yes

Mr K McCorry, Senior Pharmacist, ERY, NECS
Mr P Davis, Head Of Primary Care, Hull, CCG
Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics, HEY
Prof A Morice, Professor of Respiratory Medicine, HEY
Dr S Raise, GP Prescribing Lead, ER (via speakerphone)
Dr R Schreiber, Medical Secretary, LMC
Mr S Gaines, Senior Principal Pharmacist, HEY
Mrs J Clarke Chief Officer Local Pharmaceutical Committee ERHLPC
Mr G Hill, Principal Pharmacist, CHCP
Mr A Ortiz-Moya, Specialist Medicines Information Pharmacist, HTFT
Dr J Koriakose, Consultant Psychiatrist, HTFT

Apologies	Mrs J Stark, Principal Pharmacist, HTFT Dr K Raghunath, GP Prescribing Lead, Hull CCG
------------------	--

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2018.05.01	Apologies	As above.				
2018.05.02	Declarations of Interest	None.				
2018.05.03	Minutes of the previous meeting	Accepted as a true record. On page 7, antibiotic guidelines. AR has managed to speak to Dr Barlow who said the guidelines had been adapted from NICE with simplified regimes. Full review due in due course but no changes needed now				
2018.05.05	Action Tracker	<p>SCF Acetylcholinesterase Inh Dementia KM informed the committee the pilot scheme was still ongoing</p> <p>Paediatric Growth Hormone SCF AR has liaised with the paediatric team. Service will be in place by end of June when HEY will be able to accept referrals and supply via homecare. Until then GPs should continue to prescribe. GP's will direct patients to the new service once it is up and running.</p> <p>Bisphosphonates as Supportive Therapy for Breast Cancer AR has written guideline and is awaiting feedback from consultants.</p> <p>Diabetes Formulary GLP-1 Agonists Final version has been written and is on agenda for discussion.</p> <p>Adult Renal Transplant GP Prescribing RS will take to LMC in June and feedback at next HERPC</p> <p>Traffic Light Status Red list has now been updated and added to the website</p> <p>Type 2 Diabetes Targets Website has been updated</p>	<p>ongoing</p> <p>NEW Action:AR to draft letter for GP's to send to patients</p> <p>Add to agenda for next meeting</p> <p>Action complete</p> <p>Ongoing</p> <p>Action complete</p> <p>Action complete</p>	<p>AR to circulate letter</p>	<p>KM</p> <p>AR</p> <p>WH</p> <p>AR</p> <p>RS</p> <p>WH</p> <p>AR</p>	<p>5/18</p> <p>7/18</p> <p>7/18</p> <p>5/18</p> <p>3/18</p> <p>5/18</p> <p>5/18</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>Degarelix SCF Hull CCG meeting postponed and ER will take place next week. KM will feedback in July regarding CCG decision</p>	Ongoing		KM	5/18
		<p>Guidelines on Unlicensed Meds This guideline has now been added to the website</p>	Action complete		AR	5/18
		<p>Medicines for Stroke prevention in AF – Patient Decision Aid This guideline has now been added to the website</p>	Action complete		AR	5/18
		<p>Adult Asthma and COPD pathway These guidelines have now been added to website</p>	Action complete		AR	5/18
		<p>Dementia Guideline Hull CCG meeting postponed and ER will take place next week. KMc will feedback in July</p>	Ongoing		KMC	5/18
		<p>Verapamil in Cluster Headache This SCF has now been added to website</p>	Action complete		AR	5/18
		<p>Lithium In Affective Disorders and Cluster Headaches This SCF has now been added to website</p>	Action complete		AR	5/18
		<p>Ocular Lubricant Guideline This guideline has now been added to website</p>	Action complete		AR	5/18
		<p>Terms of Reference The update Terms of Reference have now been added to the website</p>	Action complete		AR	5/18
		<p>Correspondence Received AR attended a Task & Finish meeting in Brigg to discuss the lack of third party prescribing on SCR's. AR to attend further meeting to discuss solutions</p>	Action complete		AR	5/18
		<p>Correspondence Received AR has updated the systemic biologic pathway to include gastroenterology and Dermatology and it is on agenda for discussion.</p>	Action complete		AR	5/18
		<p>Correspondence Received AR has updated the guideline on prescribing gonadorelin analogues and</p>	Action complete		AR	5/18

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>progesterone receptor modulators. Esmya removed and link to alert included</p> <p>Correspondence Received As above</p> <p>AOB Sodium Valproate and Valproic acid – MHRA alert has been added to website to replace current guideline</p> <p>AOB Brivaracetam review of prescribing figures, currently only one patient has received treatment from HEY. Hull have prescribed 18 items and ER have prescribed 7 items between January and March. In Agenda</p> <p>AOB WH looking into the possibility of using teleconferencing to include clinical representation at D&T.</p> <p>Brivaracetam Changed to Blue. By consultant advice. Update epilepsy guidelines and formulary</p>	<p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>WH change formulary JM to update guideline</p>		<p>AR</p> <p>AR</p> <p>AR</p> <p>WH</p> <p>WH JM</p>	<p>5/18</p> <p>5/18</p> <p>5/18</p> <p>5/18</p> <p>5/18 7/18</p>
2018.05.05	Traffic Light Status	<p>Invertase Syrup genetic disaccharide enzyme deficiency.</p> <p>Chloroprocaine Hydrochloride Approved for spinal anaesthesia where surgery will not exceed 40 minutes</p> <p>Dimethyl Fumarate Approved in line with NICE TA475 for treating moderate to severe plaque psoriasis (There are now two brands of Dimethy Fumarate there is also one for the treatment of MS)</p> <p>Safinamide Parkinson's disease 3rd line after rasagaline and selegiline</p>	<p>Approved as Red</p> <p>Approved as Red</p> <p>Approved as Red</p> <p>Approved as Blue</p>	<p>WH to update RED list</p>	<p>WH</p>	<p>7/18</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2018.05.06	Feedback From Commissioning Groups	Nothing to feedback	No action required			
2018.05.07	Prescribing guidelines, shared care frameworks for approval	<p>NEW</p> <p>Dermatology and Gastroenterology biologics pathways Written to go alongside RA guideline all pathways follow NICE guidance.</p> <p>SCF Anastrozole for Chemoprevention of Familial Breast Cancer Written to go alongside SCF for Tamoxifen and Raloxifine. There was a discussion around the responsibility of the baseline bone scan. SCF to include "Initial by consultant, continuation by GP"</p> <p>Guideline Ticagrelor after MI (60mg) Written in line with NICE TA 420</p> <p>REVIEW / UPDATED (no changes NC)</p> <p>Guideline Depot antipsychotic medicines Updated to include three monthly paliperidone injection and the discontinuation of fluphenazine injection at the end of 2018. Also now included link to guidance on oil based depot injections.</p> <p>SCFs for Tamoxifen & Raloxifen for Chemoprevention of Familial Breast Cancer (NC) Updated no changes</p> <p>Antipsychotic Monitoring Forms Maintenance and Initiation Updated for side effects and monitoring frequency of some parameters in line with NICE guidance. There then followed a discussion regarding the need for ECG monitoring as this is not available in all GP practices but is part of the service contract. It was agreed to discuss these issues outside of the meeting and for the present to extend review date by three months.</p>	<p>Approved</p> <p>Approved</p> <p>Approved</p> <p>Approved</p> <p>Approved</p> <p>Approved</p> <p>Extend review date by three months</p>	<p>To be added to website</p> <p>Amend and add to website</p> <p>Add to website</p> <p>Add to website</p> <p>Add to website</p> <p>Add to website</p>	<p>WH</p> <p>AR/WH</p> <p>WH</p> <p>WH</p> <p>WH</p> <p>WH</p>	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>Glucosamine for osteoarthritis - Prescribing Guideline (NC) It was discussed if the guidance was relevant as it does not recommend the use of glucosamine but the committee agreed that the document was still useful.</p> <p>Guidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care (update contact) The issue of the lack of information regarding these medicines on SCR's was mentioned and AR agreed to raise this issue with Public Health England to ask if they could liaise with GP's on a more regular basis.</p> <p>Guideline on treatment of overactive bladder (update contact) The guideline was approved with the following amendment to alter the sequence of treatments in the first box as follows: Tolterodine Trospium Oxybutynin</p> <p>High Dose Antipsychotic Guidelines Agreed to defer to July meeting and extend review date by three months</p> <p>Medicines Management Tool For Antipsychotics Agreed to defer to July meeting and extend review date by three months</p> <p>Non Specialist Analgesia Algorithm for Managing Chronic Non Malignant Pain In Adults (NC) Pregabalin dose to be amended to 75mg BD</p> <p>Treatment Pathway for Actinic Solar Keratosis (NC) Approved</p> <p>Guidelines for the Investigation and Management of Vitamin B12 and Folate Deficiency (NC) Approved</p> <p>Prescribing Guideline for Benzodiazepines in Adults Approved</p>	<p>Approved</p> <p>Approved</p> <p>AR to speak to PHE</p> <p>Approved with amendments</p> <p>Extend review date by three months</p> <p>Defer to July</p> <p>Approved with amendment</p> <p>Approved</p> <p>Approved</p> <p>Approved</p>	<p>Add to website</p> <p>Add to July agenda</p> <p>Add to website</p> <p>Add to website</p> <p>Add to website</p>	<p>WH</p> <p>WH</p> <p>AR</p> <p>WH/AR</p> <p>WH</p> <p>WH</p> <p>WH</p> <p>WH</p> <p>WH</p>	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>Algorithm for the management of T2 DM The document was approved but the committee recognises that there are always new treatments for diabetes so the algorithm may require further updates before its review date.</p> <p>Treatment of Acute Gout in CKD (NC) AR explained that monitoring had remained as GFR and not altered to eGFR but that clarification for this had been included in the guideline.</p> <p>Dalteparin Prescribing Information for Primary Care (NC) Approved</p> <p>Wound Care Formulary GH explained that the Hull formulary had now been merged with the East Riding formulary to form one document. Items not on the formulary should only be prescribed by CHCP NHS prescribers. The community tissue viability team had already approved the document. The HEY tissue viability team have been informed of the changes.</p> <p>Guideline ticagrelor ACS (90mg) Approved</p>	<p>Approved</p> <p>Approved</p> <p>Approved</p> <p>Approved</p> <p>Approved</p>	<p>Add to website</p>	<p>WH</p> <p>WH</p> <p>WH</p> <p>WH</p> <p>WH</p>	
2018.05.08	Correspondence Received	<p>BGM Meters AR had received a letter regarding the local commissioning policy on BGMs. AR to send policy to diabetes team for info</p> <p>SOP Administration Red/Amber meds Circulated for information only to be included in policy section of HERPC website</p> <p>Zoladex Letter ER CCGhas received a letter relating to the SCF arrangements for the prescribing of Zoladex.AR will inform relevant teams of complaint.</p>	<p>Send to diabetes team for comments</p> <p>Noted</p> <p>AR to inform relevant teams</p>		<p>AR</p> <p>AR</p>	<p>7/18</p> <p>7/18</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2018.05.09	Primary Care Rebate Scheme – Standing Item	<p>Convatec dressings, Apidra/Insuman Insulin and GlucoRx medley products (Blood Glucose Test Strip/lancets/pen needles) have been reviewed as per CCG policy.</p> <p>KM explained that the items under the rebate scheme are first highlighted on PrescQIPP a not for profit platform that provides evidence based resources for commissioners, to enable them to make decisions that will optimise prescribing. The items are reviewed for their contractual, clinical and financial aspects. The more items that are prescribed the bigger the saving to primary care. However, it was emphasised that the rebate scheme has no influence on prescribing practices.</p>	Noted		KM	7/18
2018.05.10	Additional Minutes for Information	<ul style="list-style-type: none"> a) MMIG March April b) HEY D&T March/April c) HFTH DTC Feb 18 d) CHCP (none) 	Noted	No further action		
2018.05.11	A.O.B.	<p>National guidance on OTC prescribing - will be discussed at Joint formulary meeting in June</p> <p>High potency Vitamin D needs final approval, needs rewording to enable prescribers to choose more cost effective products.</p> <p>Testosterone SCF is due for review AR agreed to send to Dr Joshy for review.</p> <p>AM had been asked by a rep if they could use the HERPC pathways for COPD and Asthma. KM requested that this was not be approved until the CCG planning and commissioning had approved the pathways.</p>	<p>WH to add to Joint Formulary agenda</p> <p>AR</p> <p>AR to send to Dr Joshy</p>		<p>WH</p> <p>AR</p> <p>AR</p>	<p>7/18</p> <p>7/18</p> <p>7/18</p>
2018.05.12	Date and Time of Next Meeting	<p>Wednesday 25th July 2018 1pm – 3pm, Board Room, Health House, Willerby, Hull</p>				